Fig. 5. egl-17 expression in two anterior cells of the embryo during CAN migration. (A) The CAN positions were scored and are displayed as described in Fig. 1. Expression of egl-17 from its endogenous promoter rescued the enhancement of vab-8(gm84) CAN migration defects by the egl-17(n1377) mutation. vab-8(gm84); egl-17(n1377) mutants with a rescuing egl-17 transgenic array (w/[egl-17+]) displayed CAN migration defects indistinguishable from vab-8(gm84) mutants (P=0.76), while siblings that had lost the array (w/o [egl-17+]) showed defects similar to the original vab-8(gm84); egl-17(n1377) strain (P=0.51). (B) Fluorescence image of a 1.5 fold stage embryo showing expression of an egl-17::gfp transgene (ayIs9) in a cell at the anterior tip of the head. A second cell expressing GFP is located on the other side and is out of the plane of focus. The two arrowheads indicate two cell corpses that were engulfed by the GFP-expressing cell. The two cells appear to be hyp5 hypodermal cells based on their position and morphology during development. (C) Nomarski image of the same embryo in A. The two arrowheads indicate the same cell corpses as shown in A. Scale bar: 10 µm. (D) Schematic lateral view of the embryo at the stage shown in A. The arrow indicates the path of CAN migration. The dark region shows the site of egl-17 expression.